Merck (MRK) Enterprise Value (2009 - 2026)
Merck (MRK) reported Enterprise Value of -$5.6 billion for Q1 2026, up 38.35% year-over-year from -$4.1 billion in Q1 2025, and up 61.07% quarter-over-quarter from -$14.5 billion in Q4 2025.
Merck (MRK) Enterprise Value (2009 - 2026) Analysis & Trends
Merck (MRK) has 18 years of Enterprise Value data on file, last reported at -$5.6 billion in Q1 2026.
- Enterprise Value for Q1 2026 came in at -$5.6 billion, up 38.35% year-over-year; the trailing twelve-month figure through Mar 2026 was -$5.6 billion (up 38.35% YoY), and the FY2025 annual result was -$14.5 billion, down 6.45% from the prior year.
- Enterprise Value improved to -$5.6 billion in Q1 2026 per MRK's latest filing, from -$14.5 billion in the prior quarter.
- Over five years, Enterprise Value peaked at -$5.6 billion in Q1 2024 and troughed at -$18.2 billion in Q3 2025.
- A 5-year average of -$10.4 billion and a median of -$10.1 billion in 2022 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2023 and 2024: Enterprise Value jumped 46.37% in 2023, then slumped 93.64% in 2024.
- A 5-year view of Enterprise Value shows it stood at -$13.1 billion in 2022, then soared by 46.37% to -$7.0 billion in 2023, then tumbled by 93.64% to -$13.6 billion in 2024, then fell by 6.45% to -$14.5 billion in 2025, then soared by 61.07% to -$5.6 billion in 2026.
- Business Quant data shows MRK's Enterprise Value at -$5.6 billion in Q1 2026, -$14.5 billion in Q4 2025, and -$18.2 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | -4.96 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | -5.28 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | -22.05 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | -9.35 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -5.65 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | -12.04 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | -7.73 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | -12.77 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | -10.45 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | -100.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.65 Bn |
| Dec 31, 2025 | -14.51 Bn |
| Sep 30, 2025 | -18.16 Bn |
| Jun 30, 2025 | -8.56 Bn |
| Mar 31, 2025 | -9.16 Bn |
| Dec 31, 2024 | -13.63 Bn |
| Sep 30, 2024 | -14.54 Bn |
| Jun 30, 2024 | -11.29 Bn |
| Mar 31, 2024 | -5.56 Bn |
| Dec 31, 2023 | -7.04 Bn |
| Sep 30, 2023 | -8.72 Bn |
| Jun 30, 2023 | -6.33 Bn |
| Mar 31, 2023 | -10.32 Bn |
| Dec 31, 2022 | -13.13 Bn |
| Sep 30, 2022 | -11.18 Bn |
| Jun 30, 2022 | -10.05 Bn |
| Mar 31, 2022 | -8.86 Bn |
| Dec 31, 2021 | -8.02 Bn |
| Sep 30, 2021 | -9.95 Bn |
| Jun 30, 2021 | -8.48 Bn |